A translational biomedical engineer with a strong background in business development, Charles's passion is in building a vibrant biotech ecosystem through integrating stakeholders across academia, finance, youth development, philanthropy, and public policy. He has deep experience in biotechnology consulting, university knowledge transfer, and in MNC pharma medical affairs. He now heads Ryoden Medical where he oversees healthcare and biotech venture investments for his family office. He also co-founded Incando Therapeutics and Cere Ventures to bring innovative brain- and healthy aging-related developments to the market and leads a versatile team experienced in clinical and regulatory affairs.
Dr Hu currently serves as Chair of Biomedical Engineering Departmental Advisory Council and Adjunct Professor in Biomedical Sciences at the City University of Hong Kong, Vice Chairman to the Hong Kong Biotechnology Organization, Director of the Asian Fund for Cancer Research Limited, committee member to the Hong Kong Professionals and Senior Executives Association, the Hong Kong Trade & Development Council, the Chinese Medicine Council, the Hong Kong Innovation & Technology Commission, the HK Tech 300 Angel Fund, the Hong Kong Baptist University Entrepreneurship Fund, and advisor to several institutional and angel investment firms.
Charles received his PhD in Tissue Engineering from Johns Hopkins University, BS in Bioengineering from the University of California, Berkeley, and has been awarded the Hong Kong-Zhuhai-Macau Greater Bay Area Most Talented Young Entrepreneur Award with the Best Technology Innovation Distinction in 2023.